Results 61 to 70 of about 104,728 (194)

Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. [PDF]

open access: yesPLoS ONE, 2014
Nephrotoxicity remains a problem for patients who receive cisplatin chemotherapy. We retrospectively evaluated potential risk factors for cisplatin-induced nephrotoxicity as well as the potential impact of intravenous magnesium supplementation on such ...
Yasuhiro Kidera   +15 more
doaj   +1 more source

Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids [PDF]

open access: yes, 1982
The postoperative convalescence period was analyzed for 42 consecutive patients who had cadaveric renal transplantation under therapy with cyclosporin A and steroids.
Hakala, TR   +4 more
core  

Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes [PDF]

open access: yes, 2006
BACKGROUND. Alemtuzumab (Campath-1H) induction with tacrolimus monotherapy has been shown to provide effective immunosuppression for kidney, liver, lung, and small bowel transplantation.
Abu-Elmagd   +33 more
core   +1 more source

Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review

open access: yesFrontiers in Pharmacology, 2018
Background: Nephrotoxicity is a notable adverse effect in cisplatin treated patients characterized by tubular injury and/or increased serum creatinine (SCr) with incidence varying from 20 to 70%.
Zulfan Zazuli   +13 more
doaj   +1 more source

Changing perspectives on liver transplantation in 1988. [PDF]

open access: yes, 1988
After liver transplantation for cancer, there is a high incidence of disease recurrence within 18 to 36 months for most tumors, although there are a small number of long-term survivors.
Gordon, RD, Starzl, TE
core  

Diagnosis and Interim Treatment Outcomes from the First Cohort of Multidrug-Resistant Tuberculosis Patients in Tanzania. [PDF]

open access: yes, 2013
Kibong'oto National Tuberculosis Hospital (KNTH), Kilimanjaro, Tanzania. Characterize the diagnostic process and interim treatment outcomes from patients treated for multidrug-resistant tuberculosis (MDR-TB) in Tanzania.
Boeree, Martin J   +9 more
core   +3 more sources

The Renin-Angiotensin System Involvement in Cisplatin-Induced Nephrotoxicity: An Overview of Physiological and Pathological Mechanisms—A Systematic Review

open access: yesInternational Journal of Nephrology
Cisplatin (CDDP) is a highly potent chemotherapy drug. But its nephrotoxicity poses a significant limitation to its use. The renin-angiotensin system (RAS) has been proposed to play a role in drug-induced nephrotoxicity.
Aryan Vakilian   +5 more
doaj   +1 more source

Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study

open access: yesBMC Pharmacology and Toxicology, 2019
Background Nephrotoxicity and ototoxicity are clinically significant dose-related adverse effects associated with second-line anti-tubercular injectables drugs (aminoglycosides and capreomycin) used during intensive phase of treatment of multi-drug ...
Workineh Shibeshi   +5 more
doaj   +1 more source

Novel Omega-3 Fatty Acid Epoxygenase Metabolite Reduces Kidney Fibrosis. [PDF]

open access: yes, 2016
Cytochrome P450 (CYP) monooxygenases epoxidize the omega-3 polyunsaturated fatty acid (PUFA) docosahexaenoic acid into novel epoxydocosapentaenoic acids (EDPs) that have multiple biological actions.
Hammock, Bruce D   +5 more
core   +3 more sources

Prevalence and Risk Factors of Nephrotoxicity Among Adult Cancer Patients at Mbarara Regional Referral Hospital

open access: yesCancer Management and Research, 2021
John Isiiko,1– 3 Barnabas Atwiine,4 Joseph Oloro5 1Department of Pharmacy, Mbarara University of Science and Technology, Mbarara, Uganda; 2Pharmacy Biotechnology and Traditional Medicine Center, Mbarara University of Science and Technology, Mbarara ...
Isiiko J, Atwiine B, Oloro J
doaj  

Home - About - Disclaimer - Privacy